

Communication Address : Solara Active Pharma Sciences Limited Batra Centre No. 28, Sardar Patel Road, Post Box 2630 Guindy, Chennai - 600 032, India Tel :+91 44 43446700, 22207500 Fax :+91 44 22350278

September 27, 2019

The BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400 001 The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex Bandra (E), Mumbai – 400 051

Scrip Code: 541540

Scrip Code: SOLARA

Dear Sirs,

Sub: Press release on Ranitidine Hydrochloride Drug Substance

Solara has submitted Drug Master File (DMF) in various regulated markets. The Company has received request for information from USFDA and EDQM to provide test data on N-nitrosodimethylamine (NDMA) content in Ranitidine Hydrochloride drug substance.

The Company is in the process of responding to the information request comprehensively by second week of October 2019. Further updates on the product will be provided post completion of the requisite tests.

The Company has temporarily suspended production and distribution of Ranitidine Hydrochloride drug substance.

Ranitidine Hydrochloride is one of the top 10 APIs contributing $\sim 5\%$ to the overall revenue of the Company. We do not foresee any significant impact on the growth trajectory of the Company.

This is for your information and records

Thanking you,

Yours faithfully, For Solara Active Pharma Sciences Limited

S. Murali Krishna Company Secretary

